Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment
targeting TRBC1 in patients with relapsed or refractory TRBC1 positive T-cell hematological
maliganacies
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine